Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient

(Reuters) - Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 (1,900 pounds) for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from a cheap steroid. The price tag is below the $5,080 per course recommendation by U.S. drug pricing research group, the Institute for Clinical and Economic Review (ICER), last week.But it is more in line with a lower range suggested by ICER of around $2,520 to..